Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

Table 4

Classification results from PLS-DA of intermediary metabolite levels in cerebrospinal fluid measured by proton magnetic resonance spectroscopy.

Comparisons		Correct classification (%)	Sensitivity (%)	Specificity (%)	LVs	value
All PD versus all healthy individuals	57	74.2	74.7	73.7		0.001
LRRK2-PD versus controls	29	92.4	90.0	94.7		<0.001
LRRK2-PD versus asymptomatic mutation carriers	21	85.9	81.8	90.0		0.001
Sporadic PD versus controls	36	76.6	70.6	82.6		0.002
Sporadic PD versus LRRK2-PD	27	70.3	70.6	70.0		0.038
Asymptomatic mutation carriers versus controls	30	64.1	54.5	73.7		0.103

Asymptomatic mutation carriers: healthy individuals carrying the LRRK2 p.G2019S mutation; LVs: latent variables; random subsets, 10 divisions and 10 repetitions. Leave-one-out cross-validation.